Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 19Terminated 7Active not recruiting 5Recruiting 4Withdrawn 3Unknown 2Available 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 124Leukemia, Lymphocytic, Chronic, B-Cell 30Myelodysplastic Syndromes 27Leukemia 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Recurrence 17Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma 9Leukemia, Biphenotypic, Acute 8Hematologic Neoplasms 8Leukemia, Myelomonocytic, Chronic 7Neoplasm, Residual 6Multiple Myeloma 6Lymphoma, Mantle-Cell 6Burkitt Lymphoma 6Neoplasms 5Waldenstrom Macroglobulinemia 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Myeloproliferative Disorders 4Lymphoma, Non-Hodgkin 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid 4Leukemia, Monocytic, Acute 3GATA2 Deficiency 3Sarcoma, Myeloid 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Immunoglobulin Light-chain Amyloidosis 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Anemia, Refractory, with Excess of Blasts 2

Interventions

Cyclophosphamide 29fludarabine 19Rituximab 15fludarabine phosphate 12Specimen Handling 8obinutuzumab 7Immunotherapy, Adoptive 7Lenalidomide 6Etoposide 6pirtobrutinib 5ibrutinib 5glofitamab 5axicabtagene ciloleucel 5Whole-Body Irradiation 5Mycophenolic Acid 5venetoclax 4polatuzumab vedotin 4Prednisone 4Melphalan 4Granulocyte Colony-Stimulating Factor 4Doxorubicin 4Blood Component Removal 4Biopsy 4pembrolizumab 3daratumumab 3X-Rays 3Vincristine 3Stem Cell Transplantation 3Interleukin-2 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Non-Hodgkin × venetoclax × Clear all
NCT03223610 2026-06-05

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
155 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05529069 2026-05-05

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

CellCentric Ltd.

Phase 1/2 Recruiting
250 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT03557619 2024-08-29

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

AbbVie

Phase 1 Recruiting
12 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡